AwesomeCapital: Genmab gets FDA priority review for myeloma combo

Thursday, May 30, 2019

Genmab gets FDA priority review for myeloma combo

U.S. FDA grants Priority Review for daratumumab in combination with bortezomib, thalidomide and dexamethasone as treatment for newly diagnosed patients with multiple myeloma who are candidates for autologous stem cell transplant
September 26, 2019 PDUFA date

https://www.marketscreener.com/GENMAB-1412914/news/U-S-FDA-Grants-Priority-Review-for-Daratumumab-in-Combination-with-Bortezomib-Thalidomide-and-Dexa-28682460/

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)